Law360, New York (February 06, 2012, 7:32 PM ET) -- Ranbaxy Laboratories Ltd. on Monday exited a patent infringement suit launched by Pfizer Inc. against it and Watson Pharmaceuticals Inc. in Delaware federal court in response to abbreviated new drug applications to introduce a generic version of the organ rejection drug Rapamune.
In a sealed order, U.S. District Judge Richard G. Andrews signed off on a joint stipulation of dismissal without prejudice, allowing the company and its subsidiaries Ranbaxy Pharmaceuticals Inc. and Ranbaxy Inc. to exit the suit with each side bearing its own attorneys' fees...
Ranbaxy Exits Pfizer's Suit Over Generic Rapamune
To view the full article, take a free trial now.
